

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for August 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	JAMP Ambrisentan	Volibris	AMBRISENTAN	5 mg	tablet	02521938
Jamp Pharma Corporation	JAMP Ambrisentan	Volibris	AMBRISENTAN	10mg	tablet	02521946
Taro Pharmaceuticals Inc.	Taro-Sunitinib	Sutent	SUNITINIB MALATE	12.5 mg	capsule	02524058
Taro Pharmaceuticals Inc.	Taro-Sunitinib	Sutent	SUNITINIB MALATE	25mg	capsule	02524066
Taro Pharmaceuticals Inc.	Taro-Sunitinib	Sutent	SUNITINIB MALATE	50mg	capsule	02524082

Jamp Pharma Corporation	Jamp Atomoxetine	Strattera	ATOMOXETINE HYDROCHLORIDE	80 mg	capsule	02506866
Jamp Pharma Corporation	Jamp Atomoxetine	Strattera	ATOMOXETINE HYDROCHLORIDE	100 mg	capsule	02506874
Pharmascience Inc.	Pms-Cinacalcet	Sensipar	CINACALCET HYDROCHLORIDE	30 mg	tablet	02517604
Pharmascience Inc.	Pms-Cinacalcet	Sensipar	CINACALCET HYDROCHLORIDE	60 mg	tablet	02517612
Pharmascience Inc.	Pms-Cinacalcet	Sensipar	CINACALCET HYDROCHLORIDE	90 mg	tablet	02517620
Pharmascience Inc.	Pms-Pazopanib	Votrient	PAZOPANIB HYDROCHLORIDE	200 mg	tablet	02525666